These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The safety of ustekinumab for the treatment of psoriatic arthritis. López-Ferrer A; Laiz A; Puig L Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904 [TBL] [Abstract][Full Text] [Related]
27. Apremilast for the treatment of psoriatic arthritis. Souto A; Gómez-Reino JJ Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917 [TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for psoriatic arthritis. Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876 [TBL] [Abstract][Full Text] [Related]
29. Ustekinumab for psoriatic arthritis: close to the PSUMMIT? Warren RB; Chinoy H Lancet; 2013 Aug; 382(9894):748-9. PubMed ID: 23769295 [No Abstract] [Full Text] [Related]
31. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227 [TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Kawalec P; Holko P; Moćko P; Pilc A Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605 [TBL] [Abstract][Full Text] [Related]
33. Dramatic repair of joint damage in psoriatic arthritis. van der Heijde D; Landewé RB J Rheumatol; 2011 Jun; 38(6):969-70. PubMed ID: 21632684 [No Abstract] [Full Text] [Related]
34. Ustekinumab associated with flares of psoriatic arthritis. Stamell EF; Kutner A; Viola K; Cohen SR JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Wu D; Yue J; Tam LS Rheumatology (Oxford); 2018 Mar; 57(3):563-571. PubMed ID: 29244162 [TBL] [Abstract][Full Text] [Related]
36. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. Gan EY; Chong WS; Tey HL BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094 [TBL] [Abstract][Full Text] [Related]
38. Ustekinumab for the treatment of psoriatic arthritis. Wofford J; Menter A Expert Rev Clin Immunol; 2014 Feb; 10(2):189-202. PubMed ID: 24410536 [TBL] [Abstract][Full Text] [Related]
39. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C; Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458 [TBL] [Abstract][Full Text] [Related]
40. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence. O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]